\"*It is important that patients do not interrupt their treatment with ACE inhibitors or ARBs and there is no need to switch to other medicines*\", [1](#Fn1){ref-type="fn"} says the EMA.

The regulatory agency recently issued this advice following recent media reports and publications questioning whether some medicines (including ACE inhibitors or ARBs/sartans) − which are commonly used to treat patients with hypertension, heart failure or renal disease − could worsen the coronavirus disease (i.e. COVID-19) associated with the currently circulating strain (also known as SARS-CoV-2 [2](#Fn2){ref-type="fn"}).

The EMA noted that \"*as the public health crisis rapidly extends across the globe*\", scientists and epidemiologists around the world are carrying out research into how SARS-CoV-2 \"*reproduces in the body, interacts with the immune system and causes disease, and whether ongoing treatment with medicines such as ACE-inhibitors and ARBs could impact the prognosis of COVID-19*\".

Speculation that either ACE inhibitors or ARBs/sartans can worsen COVID-19 infections \"*is not supported by clinical evidence*\", noted the EMA, given that these medicines act via a different mechanism of action (i.e. the renin-angiotensin-aldosterone system \[RAAS\]). \"*However, the interactions of the virus with the RAAS in the body are complex and not completely understood*\", added the agency.

The EMA added that it is monitoring this safety concern closely and \"*is helping to coordinate urgent ongoing research and is fully committed to keep the public up to date with any development in this field*\".

Recently, the agency also announced that it was investigating reports claiming that NSAIDs (e.g. ibuprofen) could worsen COVID-19 symptoms, despite the fact that there is currently no scientific evidence to support this claim. [3](#Fn3){ref-type="fn"}

ACE inhibitors = angiotensin converting enzyme inhibitors; ARBs = angiotensin receptor blockers or \"sartans\"

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
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